ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central …
JMP Securities analyst Jason Butler weighs in on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after the biotech company reported second-quarter financial results that …
In ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) second-quarter report, investors got a first glimpse of Nuplazid’s early launch in Parkinson’s disease psychosis (PDP).
In a research report issued this morning, Needham analyst Alan Carr weighed in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker released its second-quarter financial …
Analyst Charles Duncan of Piper Jaffray came away with an increased confidence in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after attending an investor meeting with management.
After an investors meeting in New York City this week with ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) touching base about its upcoming commercial launch for Nuplazid, …
Needham analyst Alan Carr was out today with a favorable report on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after meeting with management for a corporate update and hosting a series of …
